OVID's logo.
Ticker Symbol: OVID

Ovid Therapeutics Inc

$3.56 - 20-11-2024 4 p.m. ET

Exchange: NASDAQ Country: US Currency: USD Asset Type: Common Stock CIK:0001636651

Company Profile

Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. The company believes these disorders represent an attractive area for drug development as the understanding of the underlying biology has grown meaningfully over the last few years and today represents a substantial opportunity medically and commercially. Based on recent scientific advances in genetics and the biological pathways of the brain, Ovid aims to identify, discover and acquire novel compounds for the treatment of rare neurological disorders. Ovid has built a deep knowledge of such disorders, how to treat them and how to develop the clinically meaningful endpoints required for development of a compound in these disorders. As a result of this knowledge, Ovid has developed a robust pipeline of first-in-class compounds and programs. The company continues to execute on its strategy to build this pipeline by discovering, in-licensing and collaborating with leading biopharmaceutical companies and academic institutions. These pipeline programs include programs targeting rare epilepsies, Angelman syndrome and Fragile X syndrome, as well as early-stage programs into other monogenetic disorders. Ovid's most advanced pipeline programs include OV935 (soticlestat) in collaboration with Takeda and OV101 a δ-selective GABAA receptor agonist. Ovid's emerging pipeline programs include OV329, a small molecule GABA aminotransferase inhibitor for seizures associated with Tuberous Sclerosis Complex and Infantile Spasms; OV882, a short hairpin RNA therapy approach for Angelman syndrome; OV815, a genetic therapy approach for KIF1A associated neurological disorder; and other non-disclosed researched targets.

Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 1460 Broadway Ste 15044
CEO: Jeremy Levin
Tags:
  • Health Technology
  • Pharmaceuticals: Major
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

Pricing

Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $3.62
Change: $0.06 ( 1.69%)
Days Range: $3.46 - $3.66
Beta: 0.76
52wk. High: $4.13
52wk. Low: $1.41
Ytd. Change 93.08%
50 Day Moving Average: $3.67
200 Day Moving Average: $3.51
Shares Outstanding: 70602793

Valuation

Market Cap: 25.6B
PE Ratio: -
EPS (TTM): -0.6984

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A